Maynard Um
-
-
-
-
-
-
-
Replimune presents final data for RP2 cancer treatment at oncology meeting
-
-
-
-
-
-
-
Replimune shares surge on report Trump to dismiss FDA chief Makary
-
-
-
-
-
-
-
Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral
-
-
-
-
-
-
-
Replimune's (REPL) RP1s Likely to Get Accelerated Approval - Cantor Fitzgerald
-
-
-
-
-
-
-
Increasing unusual put option volume: REPL LBRT ARCT CRML BYND ABAT BITF EXEL
-
-
-
-
-
-
-
Replimune schedules FDA meeting on melanoma treatment application
-
-
-
-
-
-
-
H.C. Wainwright Downgrades Replimune Group (REPL) to Neutral
-
417,343 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

